The findings highlight the importance of considering cut-point uncertainty and methodological influences when interpreting early-stage amyloidosis and highlight the importance of considering cut-point uncertainty and methodological influences when interpreting early-stage amyloidosis.
Abstract
Background
Quantitative amyloid-beta (A{beta})-PET is increasingly used in AD prevention trials. Although the Centiloid (CL) framework provides a common scale, variability persists across processing pipelines, including differences in template/native space, partial volume correction (PVC), and reference region. These choices may influence cut-points, and in turn positivity rates, as well as longitudinal accumulation rates. We examined cut-point estimates and inter-pipeline discordance in a community cohort where many are expected to have early A{beta} deposition.
Methods
We analysed [18F]florbetapir PET/MR data from predominantly cognitively unimpaired (~95%) individuals aged ~71 years at baseline (n=433) and at follow-up (n=328; ~2.4-year interval) in Insight 46 (1946 British birth cohort). Centiloids were derived using the standard pipeline and ten in-house pipelines employing alternative reference regions and PVC in native space. Gaussian mixture modelling estimated cut-points with bootstrapped uncertainty. We assessed A{beta}-discordance across pipelines as a function of standard CLs and examined follow-up CSF A{beta}42/A{beta}40 (n=120) and PET in individuals with discordant baseline classifications.
Results
Baseline cut-points were 10-23 CL across pipelines, classifying 16-25% as A{beta}-positive. Reliable accumulation cut-points were 3.5-6 CL/year, identifying 16-22% as accumulators. Uncertainty varied across pipelines. At baseline, 18% were discordant across PET measures, predominantly between 11-35 standard CLs. The discordant group showed higher A{beta}-PET accumulation and lower CSF A{beta}42/A{beta}40 than concordant negatives.
Conclusions
Disagreement between A{beta}-PET methods was highest between 11-35 standard Centiloids and was frequently associated with accumulating A{beta}. These findings highlight the importance of considering cut-point uncertainty and methodological influences when interpreting early-stage amyloidosis.
Background: The Centiloid (CL) scale standardizes global amyloid PET quantification and is widely used to define amyloid positivity. As a global summary measure, however, CL may not fully reflect the regional distribution of amyloid deposition, which can carry additional prognostic information about the rate of cogniti...
T. Hirose, W. Akamatsu, T. Kato· medRxiv· 0 citations
SUVRc for [11C]PiB PET enables more accurate quantification of A{beta} burden than SUVR in cross-sectional and longitudinal studies (relative to SRTM DVR), while enabling imaging at earlier and shorter time-windows.
P. Honhar, M. Properzi, A. Schultz et al.· medRxiv· 0 citations
Higher baseline BG-EPVS burden was associated with a more sustained rate of amyloid-β accumulation among participants with high baseline amyloid burden, and the annual rate of change in FBP SUVR follows an inverted U-shaped relationship with baseline FBP SUVR.
Ling-Yun Liu, Qing-Ze Zeng, Xiao Luo et al.· Academic Radiology· 0 citations
Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.
Arthur C. Macedo, Lydia Trudel, S. A. Hosseini et al.· EBioMedicine· 1 citation
BackgroundAlzheimer's disease (AD) is increasingly defined biologically. Amyloid positron emission tomography (PET) is a validated biomarker; however, evidence from truly consecutive, real-world memory-clinic cohorts spanning subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early AD remains limi...
Heii Arai, Satoko Aiba, Hideo Yamamoto et al.· Journal of Alzheimer's Disea...· 0 citations
The presenilin 1 (PSEN1) p.Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable.
Min-Young Noh, Wonjae Sung, Hyunkee Kim et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.